Glycosaminoglycan storage begins in prenatal life in patients with mucopolysaccharidosis (MPS). In fact, prenatal hydrops is a common manifestation of MPS VII because of ␤-glucuronidase (GUS) deficiency. One way to address prenatal storage might be to deliver the missing enzyme across the placenta into the fetal circulation. Maternal IgG is transported across the placenta by the neonatal Fc receptor (FcRn), which recognizes the Fc domain of IgG and mediates transcytosis from maternal to fetal circulation. We hypothesized that we could exploit this process to deliver corrective enzyme to the fetus. To test this hypothesis, the C-terminal fusion protein, GUS-Fc, was compared with native, untagged, recombinant GUS for clearance from the maternal circulation, delivery to the fetus, and reduction of lysosomal storage in offspring of MPS VII mice. We observed that GUS-Fc, infused into pregnant mothers on embryonic days 17 and 18, was transported across the placenta. Similarly infused untagged GUS was not delivered to the fetus. GUS-Fc plasma enzyme activity in newborn MPS VII mice was 1,000 times that seen after administration of untagged GUS and Ϸ100 times that of untreated WT newborns. Reduced lysosomal storage in heart valves, liver, and spleen provided evidence that in utero enzyme replacement therapy with GUS-Fc targeted sites of storage in the MPS VII fetus. We hypothesize that this noninvasive approach could deliver the missing lysosomal enzyme to a fetus with any lysosomal storage disease. It might also provide a method for inducing immune tolerance to the missing enzyme or another foreign protein.
T he mucopolysacchridoses (MPSs) are a group of lysosomal storage diseases (LSDs), each caused by a deficiency of an enzyme involved in the degradation of glycosaminoglycans in the lysosome (1) . Recently, enzyme replacement therapy (ERT) for several of these diseases has been developed by using the recombinant-deficient enzyme (2) . After infusion, these enzymes are delivered from plasma to the lysosomes in cells in the target organs via receptor-mediated endocytosis by the mannose 6-phosphate receptor (M6PR) or mannose receptor (MR) on plasma membranes (3, 4) .
In MPS VII, which is caused by a deficiency of ␤-glucuronidase (GUS), affected individuals can present in utero with prenatal/neonatal hydrops. Many of these infants die prenatally or in the first 2 years of life (5) . It would be advantageous to treat these affected fetuses with ERT before birth. One way to achieve this might be to exploit a placental transport system, which delivers nutrients from maternal to fetal circulation, after which the enzyme could be transported to the lysosomes of the target organs.
IgG is known to be delivered transplacentally from mother to fetus via interaction with the neonatal form of the Fc receptor (FcRn) (6) . The FcRn binds the Fc domain on IgG in maternal blood and mediates transcytosis across the syncitial trophoblast layer of the placenta. The IgG is released into the fetal circulation, where it provides immunological protection to the fetus and newborn. We tested the hypothesis that we could exploit this process by using a chimeric protein containing the CH2-CH3 Fc domain from human IgG on the C terminus of human GUS (GUS-Fc). After purification, the recombinant GUS-Fc fusion protein was characterized for its enzymatic activity, susceptibility to receptor-mediated endocytosis, presence of a functional Fc domain, and its ability to be transported across the placenta into the fetal circulation after i.v. infusion.
Results

Purification and Characterization of GUS and GUS-Fc.
GUS is a 300-kDa protein that exists as a homotetramer consisting of four identical monomers of apparent molecular mass of 75 kDa. The GUS-Fc fusion protein has a predicted molecular mass 29 kDa larger than GUS (Fig. 1A) . GUS and GUS-Fc were purified from conditioned media from CHO cells stably expressing the respective proteins by antibody affinity chromatography (7) . Purified GUS had an apparent molecular mass of 75 kDa by SDS/PAGE under reducing conditions (8, 9) (Fig. 1B) . The majority of the protein in the GUS-Fc preparation ran at an apparent molecular mass of 104 kDa, as predicted from the addition of the Fc domain to the GUS monomer (Fig. 1B) . A minor component at 75 kDa represented a small fraction from which the Fc domain had been removed by C-terminal processing (Western blot data not shown).
The chimeric protein was examined for the presence of a functional Fc domain by precipitation with Protein A Sepharose and for susceptibility to pinocytosis by human fibroblasts. As shown in Table 1 , 85% of the GUS-Fc in media and 74% of the purified GUS-Fc were precipitated by Protein A Sepharose. Only 5% of purified, untagged GUS was precipitated. The fraction of GUS-Fc that escaped precipitation included the small fraction from which the Fc domain had been proteolytically removed and the fraction in which the Fc domain was not properly folded or was inactivated during the purification process. Table 1 also presents data comparing the chimeric GUS-Fc and native, phosphorylated GUS (GUS) for susceptibility to endocytosis by fibroblasts. The reduced rate of uptake of the chimeric protein (14% that of GUS) indicated the lower phosphorylation status of the chimeric enzyme compared with GUS. Similar reductions in the extent of phosphorylation have been reported for two other C-terminal GUS fusion proteins, GUS-GILT and GUS-TAT (8, 9) .
Plasma Clearance of GUS and GUS-Fc. Fig. 2 presents data comparing plasma clearance of GUS and GUS-Fc after infusion into MPS VII MR ϩ/ϩ and MR Ϫ/Ϫ mice (4, 10). When GUS was infused into MR ϩ/ϩ mice, it was cleared from the plasma with a t 1 ⁄2 of 1.7 min. The clearance was substantially slower in the MR Ϫ/Ϫ mouse (t 1 ⁄2 ϭ 19 min) because of removal of the contribution of clearance by the MR. The clearance of GUS-Fc after infusion was substantially slower than that of GUS in both the MR ϩ/ϩ and MR Ϫ/Ϫ mice (t 1 ⁄2 ϭ 36 and 72 min, respectively). This reduced clearance rate likely reflects (i) reduced phosphorylation and consequent reduced rate of clearance by the M6PR (for both the MR ϩ/ϩ and MR Ϫ/Ϫ mice) and (ii) associated changes in glycosylation resulting from processing the nonphosphorylated high mannose oligosaccharide chains to complex type, preventing binding to the MR (pertinent only in the MR ϩ/ϩ mice). A possible third factor is recapture of the chimeric GUS-Fc after endocytosis and its return to the circulation by the FcRn (6, 11), as occurs with FcRn-mediated recapture of IgG.
Transplacental Transfer of GUS-Fc After Intraveneous Infusion Into
Pregnant Mice. To determine whether GUS-Fc could be transferred across the placenta, we examined GUS activity in plasma of MPS Ϫ/Ϫ newborns born of MPS VII ϩ/Ϫ heterozygote mothers mated with MPS VII Ϫ/Ϫ males. Offspring of both MR ϩ/ϩ and MR Ϫ/Ϫ mice were studied. The pregnant mothers were infused with 380,000 units of untagged GUS, GUS-Fc, or periodatetreated GUS (PerT-GUS), or buffer only, on both embryonic days 17 and 18. We observed that both MR ϩ/ϩ and MR Ϫ/Ϫ pregnant females, which were infused with GUS-Fc, produced MPS VII Ϫ/Ϫ pups that contained high levels of GUS activity in the plasma (Table 2 ). Plasma levels averaged 2,166 and 4,927 units/ml, respectively. By contrast, plasma GUS levels of pups from mothers infused with untagged GUS were not above the low residual levels seen in MPS Ϫ/Ϫ pups of mothers who received buffer only (2.4-4.8 units/ml). Thus, there was essentially no detectable transfer of the untagged GUS across the placenta. To rule out the possibility that the transplacental transfer was caused solely by the longer period that GUS-Fc remained in the pregnant female's circulation, we infused pregnant females with long circulating PerT-GUS, which has a t 1 ⁄2 of Ͼ18 h (7). MPS Ϫ/Ϫ pups from these mothers also had only a small amount of GUS in the plasma (Table 2) . Thus, transport across the placenta depended on the Fc tag on the chimeric GUS-Fc.
Role of FcRn in Transplacental Delivery of GUS-Fc.
To test whether transplacental transfer of GUS-Fc was mediated by the FcRn, we compared transplacental transport of GUS-Fc after infusion into WT B6 mice and two types of pregnant B6 female mice that were deficient in functional FcRn (6, 11, 12) . These included FcRn nulls and mice that were deficient for ␤ 2 -microglobulin (␤ 2 M), an accessory protein whose presence is necessary for the function of FcRn. B6 WT mothers mated with B6 WT males produced pups expressing WT levels of FcRn and showed transplacental transfer of GUS-Fc (Fig. 3) . However, neither pups from matings of FcRn nulls nor pups from matings of ␤ 2 M knockout mice showed evidence of transfer of GUS-Fc (GUS levels no higher than the endogenous levels in pups from the B6 control mice). Heterozygous FcRn Ϫ/ϩ pups from matings of B6 males and FcRn null females had Ϸ50% of plasma GUS activity of that seen in pups from the B6 ϫ B6 WT control mother. This result would be expected if the FcRn heterozygote pups expressed Ϸ50% of WT levels of FcRn.
To confirm that the GUS-Fc transport was mediated by the FcRn by another approach, we examined transplacental transport of a mutant GUS-Fc (GUS-Fc-TM), in which three amino acid residues (I, H, H) in the Fc domain, known to be critical for the binding of Fc to the FcRn (13), were substituted. Fig. 3 shows that no pups of the pregnant mice infused with GUS-Fc-TM showed GUS levels above those of endogenous levels in pups from noninfused pregnant females. Together, these data indicate that the transplacental transport of GUS-Fc is mediated by a productive interaction of the Fc domain of GUS-Fc chimeric protein and the FcRn.
Evidence That GUS-Fc Transport Occurs Prenatally. IgG can also be delivered to pups via the mother's milk by using FcRn receptors present in the gut (14, 15) . To verify that the enzyme we detected in the newborn had been delivered across the placenta rather than to the newborn through mother's milk, we collected embryonic day 19 fetuses by Caesarean section from mothers that had been injected with GUS-Fc on embryonic days 17 and 18. Fig. 4 presents data showing that plasma from these fetuses contained high levels of GUS activity (1,467 Ϯ 292 units/ml). In fact, the levels in plasma of embryonic day 19 fetuses at the time of Caesarean section (1,467 Ϯ 292 units/ml) were higher than those seen in newborns on day 1 (909 Ϯ 108 units/ml), presumably because the fetuses were taken by Caesarean section closer to the peak enzyme levels after the second infusion. This enzyme, present prenatally, must have been transported across the placenta.
Tissue Distribution After Transplacental Transport of GUS-Fc. To determine whether GUS-Fc was delivered to target organs after transplacental transport, we examined tissues of newborn MPS Ϫ/Ϫ pups collected on day 1 from MPS VII Ϫ/ϩ mothers (MR ϩ/ϩ and MR Ϫ/Ϫ ) infused with untagged GUS or GUS-Fc on embryonic days 17 and 18, as described earlier. Pups were perfused with buffer before collecting tissues to eliminate residual enzyme in blood that could potentially contaminate tissue extracts. Control experiments showed that the perfusion technique was adequate to remove circulating enzyme (data not shown). Table 3 shows that MPS Ϫ/Ϫ pups whose mothers had received GUS-Fc had GUS activity present in brain, liver, spleen, heart, kidney, lung, and eye, i.e., in all of the tissues assayed. In contrast, GUS activity was not detected in any tissues of pups born to mothers that had received untagged GUS.
Reduction in Lysosomal Storage After in Utero ERT with GUS-Fc.
To determine whether GUS-Fc was functional in reducing lysosomal storage in the fetus, tissues from newborn pups that had been treated in utero on embryonic days 17 and 18 were compared with untreated MPS VII newborn pups for lysosomal storage. MPS VII pups from buffer-infused mothers showed lysosomal storage in all tissues. Treated MPS VII MR Ϫ/Ϫ and MPS VII MR ϩ/ϩ pups showed variable responses, with some mice showing a reduction in storage in heart, liver, and spleen after this short-term, in utero treatment (Fig. 5) . The kidneys in a few treated MPS VII MR Ϫ/Ϫ pups also had a reduction in storage in the interstitial cells; however, brain and eye showed no response to this short-term treatment.
Discussion
These studies showed that a chimeric protein, in which human GUS containing a C-terminal tag consisting of the CH2-CH3 Fc domain of human IgG, was transported across the placenta from maternal to fetal circulation. This transport was mediated by the FcRn. The transferred enzyme was widely distributed in fetal tissues and, in at least some of the animals, the chimeric enzyme taken up by these tissues was effective in clearing lysosomal storage.
The functional properties of the chimeric protein included GUS activity comparable with that of native recombinant GUS, reduced susceptibility to M6PR-mediated endocytosis (14% that of native GUS), and normal function of the Fc domain (at least 74% of the purified chimeric GUS was precipitated by Protein G Sepharose). The reduced susceptibility to M6P-dependent uptake likely means reduced M6P phosphorylation of the chimeric GUS, which has been seen with other C-terminal chimeric GUS molecules [e.g., GUS-GILT (8) and GUS-TAT (9)].
The reduced phosphorylation allows the nonphosphorylated, high mannose oligosaccharide chains to be processed to complex-type oligosaccharides, which would delay clearance of the enzyme by the MR. However, the finding of 2-fold higher levels of enzyme in circulation in the MR Ϫ/Ϫ mice compared with the 
MR
ϩ/ϩ mice suggests that the chimeric GUS-Fc still has enough exposed mannoses to allow a large fraction of the enzyme to be cleared by the MR on tissue macrophages, especially hepatic Kupffer cells (4, 16) . The slower clearance of GUS-Fc in the MR Ϫ/Ϫ mothers should allow greater opportunity for transplacental transport of the enzyme in her circulation, and the slower clearance in the MR Ϫ/Ϫ pups might allow enzyme to reach more tissues and clear sites of storage that are normally resistant. The numbers in this study are not large enough for conclusions about relative effectiveness of clearance of storage in MR ϩ/ϩ and MR Ϫ/Ϫ mice. These studies in the MPS VII mouse model provide proofof-concept for a transplacental delivery system for enzyme replacement therapy. It is very likely that this method could be used to deliver corrective enzyme across the placenta in many LSDs where prenatal diagnosis has identified an affected fetus and the opportunity to treat prenatal storage makes in utero ERT desirable. In principle, this approach could also be used to deliver any protein across the placenta from the maternal to the fetal circulation.
Questions raised by this study are: (i) how early in the pregnancy is this FcRn-mediated transport system available?, (ii) would treatment earlier in pregnancy be more effective in clearing prenatal storage?, and (iii) could one use this transplacental delivery system to induce tolerance to a foreign protein prenatally? If so, fetuses identified prenatally with null mutations in any enzyme, that would otherwise mount an antibody response to the foreign human protein when exposed after birth, might be made tolerant to the therapeutic enzyme before birth. Such tolerance could allow subsequent treatment with the enzyme without production of antibodies that would abrogate the therapeutic response to the enzyme.
Materials and Methods
Generation of Stable Cell Lines Secreting GUS, GUS-Fc, and GUS ⌬C18-Fc.
Using DNA cloning techniques, we added the cDNA sequence encoding the CH2-CH3 domains without the hinge region of human IgG (BamHI-NotI fragment amplified from the Sig-7 cassette; courtesy of James Calvet, University of Kansas Medical Center, Kansas City) (17) . Age I and XhoI sites were added to the 5Ј or 3Ј ends, respectively, to facilitate subcloning into the carboxyl terminus of human GUS. The construct contained a Gly-Gly-Gly-Gly-Thr-Gly Table 3 . GUS levels in perfused tissues from newborn pups from mothers infused on embryonic days 17 and 18
PerT-GUS infused, n ϭ spacer on the amino terminus to the carboxyl terminus of the full-length cDNA or to the carboxyl terminus in which the last 18 aa had been deleted (⌬C18) for human ␤-glucuronidase (NM000181) (GUS-Fc, GUS⌬C180Fc; Fig. 1 A) . Both the WT and Fc-tagged cDNAs were subcloned into the mammalian expression vector, pCXN (18) . This expression vector contains an expression cassette consisting of the chicken ␤-actin promoter coupled to the CMV Intermediateearly (CMV-IE) enhancer. pCXN also contains a neomycin resistance marker, allowing selection of stably expressing cells with G418. These plasmids were introduced into the CHO cell line, CHO-K1, by electroporation (19) . After selection in growth medium consisting of MEM ϩ 35 g/ml proline ϩ 15% FBS ϩ 400 g of G418, colonies were picked and grown to confluency in 48-well plates. Highly expressing clones were identified by measuring GUS activity secreted into the conditioned medium (7) . The highest-producing clone was scaled up, and secreted enzyme was collected in low serum collection medium consisting of Waymouth MB 752/1 ϩ 2% FBS. We used a CHO cell line, CHO-K1, expressing WT human GUS, as described (7), to produce native GUS for these experiments.
Measurement of GUS Activity and Protein. GUS activity was measured by using 10 mM 4-methyl-umbelliferyl ␤-D-glucuronide as substrate in 0.1 M sodium acetate buffer (pH 4.8) and 1 mg/ ml crystalline BSA as described (20) . Protein levels were assayed by the method of Lowry et al. (21) .
Purification of GUS, GUS-Fc, and GUS⌬C18-Fc. Affinity chromatography procedure was essentially as described (22) . Conditioned medium from CHO cells overexpressing GUS, GUS-Fc, or GUS⌬C18 fusion proteins was filtered through a 0.22-filter. Sodium chloride (crystalline) was added to a final concentration of 0.5 M, and sodium azide was added to a final concentration of 0.025% by adding 1/400 volume of a 10% stock solution. The medium was applied to a 5-ml column of anti-human ␤-glucuronidase Affigel 10 [preequilibrated with Antibody Sepharose Wash Buffer: 10 mM Tris (pH 7.5), 10 mM potassium phosphate, 0.5 M NaCl, 0.025% sodium azide] at a rate of 25 ml/h at 4°C. The column was washed at 36 ml/h with 10 -20 column volumes of Antibody Sepharose Wash Buffer. The column was eluted at 36 ml/h with 50 ml of 10 mM sodium phosphate (pH 5.0) ϩ 3.5 M MgCl 2. Fractions of 4 ml were collected and assayed for GUS activity. Fractions containing the fusion protein were pooled, diluted with an equal volume of P6 buffer [25 mM Tris (pH 7.5), 1 mM ␤-glycerol phosphate, 0.15 mM NaCl, 0.025% sodium azide], and desalted over a BioGel P-6 column (preequilibrated with P6 buffer) to remove the MgCl 2 and change the buffer to P6 buffer for storage. The fusion protein was eluted with P6 buffer, and the fractions containing GUS activity were pooled and assayed for GUS activity and protein. Both purified GUS and GUS-Fc were stored frozen at Ϫ80°C in P6 buffer for long-term stability. For mouse infusions, the enzymes were highly concentrated in Centricon YM-30 concentrators, and the buffer was changed to P6 buffer without azide. These concentrates were frozen in small aliquots at Ϫ80°C until use. SDS/PAGE of Purified GUS and GUS-Fc. Two-and 4-g samples of purified GUS and GUS-Fc were run on SDS/PAGE and stained with Coomassie blue R-250 as described (23) .
Functional Test of Fc Domain by Protein G Precipitation of GUS-Fc and GUS⌬C18-
Fc. GUS, GUS-Fc, or GUS⌬C18-Fc (500 units) were combined with Protein G Sepharose in PBS (pH 7.4) ϩ 1 mg/ml crystalline BSA (C-BSA). This reaction mixture was mixed by rotation for 4 h at 4°C. After centrifugation at 10,000 ϫ g for 2 min, the supernatant was removed and saved for assay. The pellets were washed two times with 1 ml each of PBS then resuspended in 1 ml of PBS ϩ C-BSA. Both supernatants and pellets were assayed for GUS.
Treatment of GUS with Periodate and Borohydride. GUS was treated with sodium metaperiodate followed by sodium borohydride as described (7, 16) . Effectiveness of treatment was assessed by measuring uptake of the treated enzyme by human MPS VII fibroblasts (24) and the mouse J774E macrophage line (25) as described (7) . To test for transplacental transport of GUS-Fc, timed pregnancies were set up by using either MR ϩ/ϩ or MR Ϫ/Ϫ females. On calculated embryonic days 17 and 18, these pregnant mice were infused with 380,000 units (3-5 mg/kg) of GUS, GUS-Fc, PerT-GUS, or PBS by bolus infusion into the tail vein. Pups were delivered on days 20 and 21, collected on newborn day 1, and killed, and blood was obtained by cardiac puncture. After centrifugation, plasma was separated and assayed for GUS as described above. Pups were genotyped by PCR to confirm their MPS VII homozygous status.
Clearance of GUS, GUS-
Tissue Distribution in Pups After Transplacental Transport of GUS-Fc. Pregnant females were infused with GUS or GUS-Fc on embryonic days 17 and 18 as described above. Pups born were deeply anesthetized i.p. on newborn day 1 with a mixture of ketamine, xylazine, and saline. All pups were perfused through the left ventricle of the heart with 25 mM Tris, 140 mM NaCl (pH 7.2) buffer. A small slit was made in the left ventricle, and the right atrium was cut open for drainage. A syringe and needle containing perfusion buffer was placed in the left ventricle of the heart, and the pup was perfused with buffer until the liver was completely cleared of color. Tissues for assays were removed, quick-frozen in liquid nitrogen, and stored at Ϫ80°C until extracts could be prepared. Thawed tissues were weighed and homogenized for 30 s by Polytron in 10 -30 vol (wt/vol) of 25 mM Trix, 140 mM NaCl, 1 mM PMSF, pH 7.2. Total homogenates were refrozen at Ϫ80°C, thawed, and sonicated for 20 s on ice for assays of GUS and protein levels.
Clearance of Lysosomal Storage from MPS VII Pups After Transplacental Delivery of GUS-Fc. MPS VII MR ϩ/ϩ or MR Ϫ/Ϫ pregnant female mice were infused with GUS-Fc as described in the previous section. On newborn day 1, the animals were perfused as described above, and brain and other tissues were collected and fixed in 4% paraformaldehyde/2% gluteraldehyde. Sections were cut and analyzed for clearance of storage material.
